Dataset Information


Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors.

ABSTRACT: Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction and enhanced therapeutic benefit in a wide variety of cancer models. Here, we evaluated two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular receptors (PiT-2 and PiT-1, respectively) for viral entry, in human osteosarcoma cells. Quantitative RT-PCR showed that low levels of expression of both receptors were observed in normal and non-malignant cells. However, high PiT-2 (for AMLV) and low PiT-1 (for GALV) expression was observed in most osteosarcoma cell lines. Accordingly, AMLV expressing the green fluorescent protein gene infected and replicated more efficiently than GALV in most osteosarcoma cell lines. Furthermore, RRVs expressing the cytosine deaminase prodrug activator gene showed differential cytotoxicity that correlated with the results of viral spread. AMLV-RRV-mediated prodrug activator gene therapy achieved significant inhibition of subcutaneous MG-63 tumor growth over GALV in nude mice. These data indicate that AMLV vectors predominate over GALV in human osteosarcoma cells. Moreover, our findings support the potential utility of the two RRVs in personalized cancer virotherapy on the basis of receptor expression.


PROVIDER: S-EPMC6760559 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7073086 | BioStudies
2005-01-01 | S-EPMC1895126 | BioStudies
1000-01-01 | S-EPMC237294 | BioStudies
1000-01-01 | S-EPMC237230 | BioStudies
1998-01-01 | S-EPMC110436 | BioStudies
1000-01-01 | S-EPMC3418563 | BioStudies
1000-01-01 | S-EPMC190516 | BioStudies
1000-01-01 | S-EPMC188913 | BioStudies
1999-01-01 | S-EPMC104050 | BioStudies
2000-01-01 | S-EPMC112417 | BioStudies